Leukemia Clinical Trials

A listing of Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 570 clinical trials
Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

-Positive Acute Lymphoblastic Leukemia. There are two age groups/cohorts: participants aged 18 to 59 years participants aged 60 years and older One tyrosine

  • 0 views
  • 25 May, 2022
  • 1 location
A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101)

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of SNDX-5613 in patients with acute leukemia. In Phase 2, patients will be

cancer
hematopoietic growth factors
total body irradiation
blast cells
myeloid leukemia
  • 34 views
  • 02 Jun, 2022
  • 14 locations
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

This study will help researchers collect more information about how effective the combination of venetoclax and obinutuzumab is in treating CLL in people who have not received a previous treatment for their cancer.

cancer
neutrophil count
chronic lymphocytic leukemia
anemia
platelet count
  • 0 views
  • 09 Jun, 2022
  • 6 locations
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Background The drug venetoclax treats chronic lymphocytic leukemia (CLL). Researchers want to find better treatments for CLL. To do that, they need to learn how

cancer
fever
chronic lymphocytic leukemia
lymphadenopathy
anemia
  • 0 views
  • 13 Jun, 2022
  • 1 location
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL (AVO)

This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab -- as a possible treatment for chronic lymphocytic leukemia (CLL). The drugs

fever
monoclonal antibodies
chronic lymphocytic leukemia
platelet count
direct bilirubin
  • 233 views
  • 19 Jun, 2022
  • 3 locations
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

patients with acute myeloid leukemia and high-grade myeloid neoplasms. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Chemotherapy drugs, such

hydroxyurea
cancer
cladribine
colony stimulating factor
cytarabine
  • 0 views
  • 13 May, 2022
  • 1 location
Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

20 mg or 40 mg of quizartinib will be given to Chinese patients who were just diagnosed with AML. The study drug will be given to them along with standard therapies. The purpose is to find out the highest dose they can stand.

cytarabine
  • 8 views
  • 25 Apr, 2022
  • 1 location
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

when given in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of

ejection fraction
decitabine
induction chemotherapy
carbon monoxide
venetoclax
  • 0 views
  • 28 Apr, 2022
  • 10 locations
Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

chemotherapy in the management of relapsed/refractory acute myeloid leukemia. This study uses a 3+3 design with a five-patient cohort at the recommended phase 2 dose.

myeloproliferative disorder
flow cytometry
cladribine
cytarabine
colony stimulating factor
  • 14 views
  • 05 May, 2022
  • 1 location
Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

This study includes patients with relapsed acute leukemia who have previously been treated with standard treatment that is still present and there is no curative treatment option available

cancer
hla-a
fludarabine
remission
leukapheresis
  • 3 views
  • 15 May, 2022
  • 1 location